#United States #Chicago #Clinical Trials #Alzheimer's Association #Oral Semaglutide

Alzheimer's Association's Take on Phase 3 Topline Data Release

The Alzheimer's Association has officially expressed its disappointment regarding the results from the clinical trials named evoke and evoke+, which focused on testing the oral semaglutide pill for early-stage symptomatic Alzheimer's disease. Despite the hopes pinned on these trials, they did not yield a statistically significant reduction in the progression of Alzheimer's disease, as confirmed in a statement released on November 24, 2025.

Joanne Pike, the president and CEO of the Alzheimer's Association, stated, "While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease. The data from every clinical trial, regardless of its outcome, is vital to accelerating our understanding and informs future clinical trials. Our optimism remains strong for the future of Alzheimer’s treatment and prevention, particularly as the scientific landscape diversifies and expands."

Preliminary outcomes showed that while treatment with semaglutide led to improvements in Alzheimer's disease-related biomarkers, these changes did not correspond to a delay in the disease's progression. Enrolled participants in the evoke and evoke+ trials included over 3,800 individuals aged between 55 to 85 years, diagnosed with mild cognitive impairment (MCI) or mild dementia attributable to Alzheimer's disease, which constitutes stages 3 and 4 of the disease.

Maria C. Carrillo, Ph.D., the chief science officer and medical affairs lead at the Alzheimer's Association, emphasized, "These results will help refine our understanding of this drug class. Other drugs in this class may behave differently, and our commitment to innovative research remains unwavering. Continuing to investigate diverse treatment and prevention methods is key."

The Alzheimer's treatment pipeline still shows promise and potential. A report published in early 2025 regarding drug development for Alzheimer’s revealed that there are currently 182 active clinical trials focused on evaluating 138 novel drugs. In alignment with its